CRISPR: can gene-editing help nature cope with climate change? – New Statesman
Daily Californian |
CRISPR: can gene-editing help nature cope with climate change?
New Statesman But as a new gene editing technology called CRISPR-Cas9 takes rapid steps toward clinical testing in humans, some are asking if it can also help the world cope with a warming climate. The CRISPR technique has revolutionised scientists’ ability to … Genetic mutation in mice treatable with CRISPR-Gold gene-editing technologyDaily Californian CRISPR-Gold Fixes Duchenne Muscular Dystrophy Mutation in MiceBioscience Technology CRISPR Nanoparticles Repair Duchenne Muscular Dystrophy Gene …Genetic Engineering & Biotechnology News Newsy –PharmiWeb.com (press release) –Medical News Bulletin all 14 news articles » |
Phys.Org |
Tooth root pulp becomes rich source of stem cells
Phys.Org Stem cells. Few research discoveries hold as much promise of single-handedly expanding medical treatment options as they do. Miraculously able to act as transformers—either re-creating or morphing into a variety of cell types found within the … |
Finance News Daily |
Amgen, CytomX Launch Up-to-$1.465B+ Cancer Immunotherapy Collaboration
Genetic Engineering & Biotechnology News Amgen will use CytomX’s Probody™ therapeutics platform to develop new cancer immunotherapies under a collaboration that could generate up to $1.465 billion-plus for CytomX. Amgen and CytomX have agreed to codevelop a CytomX Probody … CytomX Therapeutics, Inc. (CTMX) Have Entered Into A Strategic Collaboration In Immuno-Oncology- Heat Biologics …Investing News Update Cytomx Therapeutics, Inc. – CTMX – Stock Price Today – ZacksZacks Investment Research |
MD Magazine |
New Gene Therapy Could Reverse, Even Cure, MS
MD Magazine “Various aspects of the gene therapy platform have already been tested in the clinic, but several specific components have not. So, it’s going to take a little bit of time to merge the technology that’s already in the clinic with the pieces that still … |
|
FIT Biotech Oy: FIT Biotech initiates gene therapy research collaboration with Avacta
GlobeNewswire (press release) FIT Biotech Oy (“Company”) today announced that it has initiated a research collaboration with Avacta Group Plc, Cambridge UK to assess the suitability of developing gene therapies combining the Company’s gtGTU® platform and Avacta’s Affimer® … |